Quotient Wealth Partners LLC Increases Stake in Boston Scientific Co. (NYSE:BSX)

Quotient Wealth Partners LLC grew its stake in shares of Boston Scientific Co. (NYSE:BSX) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,045 shares of the medical equipment provider’s stock after purchasing an additional 285 shares during the quarter. Quotient Wealth Partners LLC’s holdings in Boston Scientific were worth $451,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in BSX. Entropy Technologies LP bought a new position in shares of Boston Scientific during the fourth quarter valued at about $214,000. Empowered Funds LLC raised its position in Boston Scientific by 13.7% during the 4th quarter. Empowered Funds LLC now owns 26,615 shares of the medical equipment provider’s stock valued at $2,377,000 after purchasing an additional 3,202 shares during the last quarter. Wilmington Savings Fund Society FSB lifted its holdings in Boston Scientific by 21.9% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 17,087 shares of the medical equipment provider’s stock worth $1,526,000 after buying an additional 3,069 shares during the period. Kingsview Wealth Management LLC grew its position in shares of Boston Scientific by 9.9% in the 4th quarter. Kingsview Wealth Management LLC now owns 6,563 shares of the medical equipment provider’s stock worth $586,000 after buying an additional 593 shares during the last quarter. Finally, Apollon Wealth Management LLC increased its stake in shares of Boston Scientific by 9.7% during the fourth quarter. Apollon Wealth Management LLC now owns 20,355 shares of the medical equipment provider’s stock valued at $1,818,000 after buying an additional 1,793 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of BSX opened at $105.33 on Monday. Boston Scientific Co. has a 12 month low of $64.39 and a 12 month high of $107.17. The business’s fifty day simple moving average is $94.88 and its two-hundred day simple moving average is $87.21. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a market cap of $155.24 billion, a price-to-earnings ratio of 84.26, a P/E/G ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. Research analysts anticipate that Boston Scientific Co. will post 2.83 earnings per share for the current fiscal year.

Insider Activity

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares in the company, valued at $3,179,416.38. The trade was a 10.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the transaction, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This trade represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,302 shares of company stock valued at $4,464,725 over the last three months. Insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on BSX shares. Truist Financial lifted their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. Deutsche Bank Aktiengesellschaft upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research report on Friday, January 10th. Sanford C. Bernstein lifted their price objective on Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. UBS Group increased their target price on Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Mizuho lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $106.00.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.